Janney Montgomery Scott
AVDL

Janney Montgomery Scott’s Avadel Pharmaceuticals AVDL Stock Holding History

Janney Montgomery Scott’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,531
Closed -$106K – 2314
2022
Q1 		$106K Sell
15,531
-29,227
-65% -$201K ﹤0.01% 2170
2021
Q4 		$362K Buy
44,758
+3,472
+8% +$31.7K ﹤0.01% 1897
2021
Q3 		$405K Sell
41,286
-50
-0.1% -$394 ﹤0.01% 1789
2021
Q2 		$278K Sell
41,336
-4,950
-11% -$39.3K ﹤0.01% 1957
2021
Q1 		$418K Buy
46,286
+22,631
+96% +$183K ﹤0.01% 1662
2020
Q4 		$158K Buy
+23,655
New +$148K ﹤0.01% 2129
2019
Q1 		– Sell
-141,856
Closed -$366K – 1999
2018
Q4 		$366K Sell
141,856
-85,717
-38% -$291K ﹤0.01% 1457
2018
Q3 		$999K Buy
227,573
+29,350
+15% +$158K 0.01% 1037
2018
Q2 		$1.22M Buy
198,223
+3,000
+2% +$21K 0.01% 893
2018
Q1 		$1.42M Buy
195,223
+5,250
+3% +$46.2K 0.01% 809
2017
Q4 		$1.56M Sell
189,973
-10,003
-5% -$93.8K 0.02% 759
2017
Q3 		$2.1M Buy
+199,976
New +$1.91M 0.02% 595
2017
Q1 		– Sell
-123,426
Closed -$1.28M – 1742
2016
Q4 		$1.28M Sell
123,426
-11,674
-9% -$128K 0.02% 675
2016
Q3 		$1.68M Sell
135,100
-104,700
-44% -$1.37M 0.03% 486
2016
Q2 		$2.58M Buy
239,800
+123,900
+107% +$1.32M 0.05% 257
2016
Q1 		$1.28M Buy
115,900
+14,200
+14% +$141K 0.03% 456
2015
Q4 		$1.24M Buy
101,700
+29,500
+41% +$460K 0.03% 486
2015
Q3 		$1.18M Buy
72,200
+6,900
+11% +$152K 0.03% 478
2015
Q2 		$1.38M Sell
65,300
-6,400
-9% -$115K 0.03% 631
2015
Q1 		$1.29M Buy
71,700
+8,745
+14% +$137K 0.02% 744
2014
Q4 		$1.08M Buy
62,955
+21,455
+52% +$306K 0.02% 836
2014
Q3 		$594K Buy
41,500
+16,500
+66% +$237K 0.01% 1157
2014
Q2 		$375K Buy
25,000
+9,000
+56% +$109K 0.01% 1439
2014
Q1 		$214K Buy
16,000
+3,000
+23% +$32.2K 0.01% 1715
2013
Q4 		$105K Buy
13,000
+2,000
+18% +$14.1K ﹤0.01% 1906
2013
Q3 		$72.2K Buy
+11,000
New +$67.7K ﹤0.01% 1836

Other funds holding AVDL

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Janney Montgomery Scott's AVDL Position: Q2 2022 in Review

Janney Montgomery Scott sold out of Avadel Pharmaceuticals (AVDL) in Q2 2022, closing a stake of 15,531 shares — an estimated $106K sold.

Janney Montgomery Scott first reported a position in AVDL in Q3 2013 and held it in 26 quarters. The position peaked at $2.58M in Q2 2016. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

  • Janney Montgomery Scott reported no remaining Avadel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Janney Montgomery Scott sold 15,531 Avadel Pharmaceuticals shares in Q2 2022, an estimated $106K.
  • Janney Montgomery Scott first reported a position in Avadel Pharmaceuticals in Q3 2013 and held it in 26 quarters.
  • Janney Montgomery Scott's Avadel Pharmaceuticals position peaked at $2.58M in Q2 2016.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on Janney Montgomery Scott's 13F filing for Q2 2022, filed 3 Aug 2022.